Eyenovia Inc (EYEN) - Total Assets
Based on the latest financial reports, Eyenovia Inc (EYEN) holds total assets worth $5.98 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eyenovia Inc - Total Assets Trend (2015–2024)
This chart illustrates how Eyenovia Inc's total assets have evolved over time, based on quarterly financial data. Also see Eyenovia Inc stock valuation for the company's overall valuation and market capitalisation.
Eyenovia Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Eyenovia Inc's total assets of $5.98 Million consist of 75.5% current assets and 24.6% non-current assets. Review EYEN current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.8% |
| Accounts Receivable | $313.53K | 8.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Eyenovia Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See EYEN stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eyenovia Inc's current assets represent 75.5% of total assets in 2024, a decrease from 99.5% in 2015.
- Cash Position: Cash and equivalents constituted 57.8% of total assets in 2024, down from 88.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
Eyenovia Inc Competitors by Total Assets
Key competitors of Eyenovia Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Eyenovia Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 0.83 | 3.99 |
| Quick Ratio | 0.34 | 0.61 | 4.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-9.94 Million | $-2.86 Million | $8.24 Million |
Eyenovia Inc - Advanced Valuation Insights
This section examines the relationship between Eyenovia Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 36.17 |
| Latest Market Cap to Assets Ratio | 19.98 |
| Asset Growth Rate (YoY) | -87.3% |
| Total Assets | $3.67 Million |
| Market Capitalization | $73.30 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Eyenovia Inc's assets at a significant premium (19.98x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Eyenovia Inc's assets decreased by 87.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eyenovia Inc (2015–2024)
The table below shows the annual total assets of Eyenovia Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.67 Million | -87.26% |
| 2023-12-31 | $28.78 Million | -7.27% |
| 2022-12-31 | $31.04 Million | -1.97% |
| 2021-12-31 | $31.66 Million | -6.63% |
| 2020-12-31 | $33.91 Million | +130.70% |
| 2019-12-31 | $14.70 Million | -26.57% |
| 2018-12-31 | $20.02 Million | +254.68% |
| 2017-12-31 | $5.64 Million | +64.39% |
| 2016-12-31 | $3.43 Million | +21.80% |
| 2015-12-31 | $2.82 Million | -- |
About Eyenovia Inc
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vi… Read more